Valuation: Thalia Therapeutics Plc

Market Cap 6.95M 9.21M 8.08M 7.6M 12.98M 882M 13.08M 91.26M 35.38M 450M 34.58M 33.83M 1.46B P/E 2024
-1.69x
P/E 2025 -3.09x
Enterprise Value 5.87M 7.78M 6.83M 6.42M 10.96M 745M 11.05M 77.08M 29.88M 380M 29.21M 28.57M 1.23B EV / Sales 2024
198,657,512x
EV / Sales 2025 452,941,079x
Free-Float
41.35%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Thalia Therapeutics Plc

Current month-11.54%
1 month-11.54%
3 months-14.81%
6 months+27.78%
Current year+9.52%
1 week 0.55
Extreme 0.55
0.6
1 month 0.5
Extreme 0.5
0.7
Current year 0.4
Extreme 0.4
0.95
1 year 0.4
Extreme 0.4
0.95
3 years 0.35
Extreme 0.35
1.52
5 years 0.35
Extreme 0.35
9.5
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 66 2026-02-23
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 56 2025-05-26
Director TitleAgeSince
Director/Board Member 48 2020-07-13
Chairman 59 2023-07-31
Director/Board Member 81 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
11/28/24 Free

Founder

6,000,000 1.5198%
11/28/24 Free

Director

3,000,000 0.7599%
11/28/24 Free

Chairman

3,000,000 0.7599%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-17.86%-61.67% 9.21M
+0.06%+6.49%+60.29%+111.13% 74.18B
-0.07%-3.78%+34.28%+75.02% 59.55B
-2.05%-3.46%-18.60%+352.20% 25.84B
-2.39%+2.74%+0.19%-5.91% 24.73B
-0.61%+1.47%+21.93%-9.68% 20.87B
+1.29%-2.49%+152.11%+333.06% 15.32B
-2.44%-0.09%+42.50%+164.11% 14.06B
-3.91%-4.91%-14.10%+779.68% 13.12B
-1.12%-3.04%+15.72%+234.56% 11.85B
Average -1.13%-0.36%+27.65%+197.25% 25.95B
Weighted average by Cap. -0.79%+0.70%+36.31%+161.38%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.92 0.01 0.1 0.04 0.47 0.04 0.04 1.53 0.01 0.01 0.01 0.01 0.01 0.92 0.01 0.1 0.04 0.47 0.04 0.04 1.52
Net income -1.06M -1.4M -1.23M -1.16M -1.98M -134M -1.99M -13.91M -5.39M -68.54M -5.27M -5.15M -222M -1.21M -1.6M -1.4M -1.32M -2.25M -153M -2.27M -15.83M -6.14M -78.02M -6M -5.87M -253M
Net Debt -626K -830K -728K -685K -1.17M -79.49M -1.18M -8.22M -3.19M -40.53M -3.12M -3.05M -131M -1.08M -1.43M -1.26M -1.18M -2.02M -137M -2.03M -14.18M -5.5M -69.88M -5.37M -5.26M -227M
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
3
Date Price Change Volume
26-09-24 GBX 0.5750 0.00% 0
26-09-23 GBX 0.5750 0.00% 253,538
26-09-22 GBX 0.5750 0.00% 565,425
26-09-21 GBX 0.5750 0.00% 770,788
26-09-18 GBX 0.5750 0.00% 187,257
  1. Stock Market
  2. Stocks
  3. THAT Stock